Materials study demonstrates that industrial ferrovanadium reduces TiZrVFeNi alloy costs by 61% without sacrificing hydrogen storage performance, indicating a scalable pathway for stationary storage.
Metal hydride-based hydrogen storage systems are promising for stationary applications; however, the high capital expenditure (CAPEX), largely driven by refined alloying elements, remains a barrier to large-scale deployment. This work investigates substituting high-purity V and Fe with industrial ferrovanadium (FeV80) in dual-phase C14/BCC Ti21Zr21VxFeyNiz alloys. Two representative compositions were produced using high-purity (HP) and low-cost (LC) precursors: a low-vanadium alloy (5 V) and a high-vanadium alloy (14 V). Microstructural and crystallographic characterization confirmed that the LC alloys fully preserved the target dendritic dual-phase configuration and phase balance, proving that industrial impurities below 0.7 wt % do not alter the core metallurgy. At room temperature, the LC alloys exhibited reversible capacities (1.1 wt % for 5 V and 0.7 wt % for 14 V) and cycling stability virtually identical to their HP counterparts, while FeV80 successfully halved the activation incubation time of the 14 V alloy from 1000 to 500 s. Economically, the FeV80 substitution achieved a substantial raw material cost reduction of up to 61.1%, slashing the 14 V alloy price from 66.79 to 25.99 USD/kg. Projecting these experimental values onto a commercial stationary storage case study with a 7.6 kg H2 target demonstrates that under an optimized maximum capacity scenario, the 14 V-LC alloy requires only 481 kg of active material, which represents a 12.5% mass reduction compared to the 550 kg commercial benchmark active bed and a 60.6% reduction in active material cost compared to the HP counterpart. Ultimately, this study establishes industrial-grade ferrovanadium as a strategic, scalable feedstock capable of drastically reducing storage system CAPEX while completely decoupling production costs from functional performance.
No takes yet. Share an insight, caveat, or question.
Vicente et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: